Search Results - M. Yu. Frolov

Refine Results
  1. 1
    PHARMACOECONOMIC EVALUATION OF POMALIDOMIDE (IMNOVID) FOR THE TREATMENT OF RECURRENT AND REFRACTORY MULTIPLE MYELOMA

    PHARMACOECONOMIC EVALUATION OF POMALIDOMIDE (IMNOVID) FOR THE TREATMENT OF RECURRENT AND REFRACTORY MULTIPLE MYELOMA by M. Yu. Frolov, O. V. Shatalova

    Published 2017-08-01
    Get full text
    Article

    Save to List
    Saved in:
  2. 2
    PHARMACOECONOMIC STUDY OF LENVIMA (LENVATINIB) IN ADVANCED PROGRESSIVE RADIO IODINE REFRACTORY DIFFERENTIATED THYROID CANCER IN THE RUSSIAN FEDERATION

    PHARMACOECONOMIC STUDY OF LENVIMA (LENVATINIB) IN ADVANCED PROGRESSIVE RADIO IODINE REFRACTORY DIFFERENTIATED THYROID CANCER IN THE RUSSIAN FEDERATION by M. Yu. Frolov, V. A. Rogov

    Published 2016-04-01
    Get full text
    Article

    Save to List
    Saved in:
  3. 3
    CLINICAL AND ECONOMIC EVALUATION OF LACOSAMIDE IN PATIENTS WITH PARTIAL EPILEPSY

    CLINICAL AND ECONOMIC EVALUATION OF LACOSAMIDE IN PATIENTS WITH PARTIAL EPILEPSY by E. A. Pyadushkina, M. Yu. Frolov

    Published 2016-12-01
    Get full text
    Article

    Save to List
    Saved in:
  4. 4
    PHARMACOECONOMIC ANALYSIS OF VESOMNI (SOLIFENACIN AND CONTROLLED RELEASE TAMSULOSIN) TREATMENT OF STORAGE SYMPTOMS ASSOCIATED WITH BENIGN PROSTATIC HYPERPLASIA

    PHARMACOECONOMIC ANALYSIS OF VESOMNI (SOLIFENACIN AND CONTROLLED RELEASE TAMSULOSIN) TREATMENT OF STORAGE SYMPTOMS ASSOCIATED WITH BENIGN PROSTATIC HYPERPLASIA by N. A. Avxentyev, M. Yu. Frolov

    Published 2016-09-01
    Get full text
    Article

    Save to List
    Saved in:
  5. 5
    EVALUATION OF DRUG THERAPY IN PROGRESSING DIFFERENTIATED THYROID CANCER REFRACTORY TO RADIOACTIVE IODINE IN PATIENTS RESIDING IN THE RUSSIAN FEDERATION : PHARMACOECONOMIC ASPECTS

    EVALUATION OF DRUG THERAPY IN PROGRESSING DIFFERENTIATED THYROID CANCER REFRACTORY TO RADIOACTIVE IODINE IN PATIENTS RESIDING IN THE RUSSIAN FEDERATION : PHARMACOECONOMIC ASPECTS by M. Yu. Frolov, V. A. Rogov

    Published 2017-05-01
    Get full text
    Article

    Save to List
    Saved in:
  6. 6
    PHARMACOECONOMIC JUSTIFICATION OF A WIDER USE OF PREVENTIVE HEMOPHILIA THERAPY IN THE RUSSIAN FEDERATION

    PHARMACOECONOMIC JUSTIFICATION OF A WIDER USE OF PREVENTIVE HEMOPHILIA THERAPY IN THE RUSSIAN FEDERATION by M. Yu. Frolov, V. A. Rogov

    Published 2018-02-01
    Get full text
    Article

    Save to List
    Saved in:
  7. 7
    STAGES OF DEVELOPMENT OF THE ACCESS OF NEW MEDICATIONS AND HEALTH TECHNOLOGIES (Retracted)

    STAGES OF DEVELOPMENT OF THE ACCESS OF NEW MEDICATIONS AND HEALTH TECHNOLOGIES (Retracted) by V.V. Omel'yanovskii, M.Yu. Frolov

    Published 2011-12-01
    Get full text
    Article

    Save to List
    Saved in:
  8. 8
    Direct medical costs of using enzalutamide or abiraterone in chemotherapy-naïve patients with metastatic castration resistant prostate cancer

    Direct medical costs of using enzalutamide or abiraterone in chemotherapy-naïve patients with metastatic castration resistant prostate cancer by N. A. Avxentyev, A. S. Makarov, M. Yu. Frolov

    Published 2019-01-01
    Get full text
    Article

    Save to List
    Saved in:
  9. 9
    Pharmacoeconomic analysis of treatment with nilotinib as the second line therapy in patients with chronic myeloid leukemia

    Pharmacoeconomic analysis of treatment with nilotinib as the second line therapy in patients with chronic myeloid leukemia by N. A. Avxentyev, M. Yu. Frolov, A. S. Makarov

    Published 2018-08-01
    Get full text
    Article

    Save to List
    Saved in:
  10. 10
    Evaluation of the economic effect of biological therapy in patients with severe COVID-19 and cytokine storm

    Evaluation of the economic effect of biological therapy in patients with severe COVID-19 and cytokine storm by M. Yu. Frolov, A. S. Salasyuk, V. A. Rogov

    Published 2021-02-01
    Get full text
    Article

    Save to List
    Saved in:
  11. 11
    Pharmacoeconomic analysis of using cyclin-dependent kinase 4 and 6 inhibitors in the first line treatment of HR-positive HER2-negative advanced breast cancer

    Pharmacoeconomic analysis of using cyclin-dependent kinase 4 and 6 inhibitors in the first line treatment of HR-positive HER2-negative advanced breast cancer by N. A. Avxentyev, E. V. Lubennikova, M. Yu. Frolov

    Published 2020-02-01
    Get full text
    Article

    Save to List
    Saved in:
  12. 12
    CLINICAL AND ECONOMIC EVALUATION OF THROMBOPOIETIN RECEPTOR AGONISTS IN THE TREATMENT OF CHRONIC IDIOPATHIC THROMBOCYTOPENIC PURPURA IN ADULTS

    CLINICAL AND ECONOMIC EVALUATION OF THROMBOPOIETIN RECEPTOR AGONISTS IN THE TREATMENT OF CHRONIC IDIOPATHIC THROMBOCYTOPENIC PURPURA IN ADULTS by E. A. Pyadushkina, M. Yu. Frolov, M. V. Avksentyeva

    Published 2016-02-01
    Get full text
    Article

    Save to List
    Saved in:
  13. 13
    Estimating long-term overall survival with olaparib as maintenance therapy in patients with newly diagnosed advanced ovarian cancer with BRCA mutations

    Estimating long-term overall survival with olaparib as maintenance therapy in patients with newly diagnosed advanced ovarian cancer with BRCA mutations by N. A. Avxentyev, S. V. Khokhlova, M. Yu. Frolov, A. S. Makarov

    Published 2021-10-01
    Get full text
    Article

    Save to List
    Saved in:
  14. 14
    PHARMACOECONOMIC ANALYSIS OF EVEROLIMUS IMMUNOSUPRESSIVE THERAPY AFTER RENAL TRANSPLANTATION

    PHARMACOECONOMIC ANALYSIS OF EVEROLIMUS IMMUNOSUPRESSIVE THERAPY AFTER RENAL TRANSPLANTATION by M. V. Avxentyeva, N. A. Avxentyev, M. Yu. Frolov, E. V. Derkach

    Published 2015-06-01
    Get full text
    Article

    Save to List
    Saved in:
  15. 15
    Evaluation of the health care budget impact of secukinumab treatment in patients with ankylosing spondylitis

    Evaluation of the health care budget impact of secukinumab treatment in patients with ankylosing spondylitis by S. K. Zyryanov, I. N. Dyakov, S. V. Nedogoda, M. Yu. Frolov, A. S. Salasyuk

    Published 2017-04-01
    Get full text
    Article

    Save to List
    Saved in:
  16. 16
    Self-care as the Basis of the Mobile Application for Patients with Chronic Coronary Syndromes

    Self-care as the Basis of the Mobile Application for Patients with Chronic Coronary Syndromes by A. I. Laskova, M. Yu. Frolov, Yu. A. Orlova, Yu. M. Lopatin

    Published 2022-07-01
    Get full text
    Article

    Save to List
    Saved in:
  17. 17
    Clinical and economic benefits of using sonidegib in the 1-line therapy of patients with locally advanced basal cell carcinoma

    Clinical and economic benefits of using sonidegib in the 1-line therapy of patients with locally advanced basal cell carcinoma by O. I. Ivakhnenko, V. V. Ryazhenov, M. Yu. Frolov, V. A. Rogov

    Published 2025-08-01
    Get full text
    Article

    Save to List
    Saved in:
  18. 18
    Pharmacoeconomic analysis of tiotropium bromide and olodaterol fixed combination as maintenance therapy for patients with COPD in the Russian Federation

    Pharmacoeconomic analysis of tiotropium bromide and olodaterol fixed combination as maintenance therapy for patients with COPD in the Russian Federation by S. V. Nedogoda, M. Yu. Frolov, A. S. Salasyuk, I. N. Barykina, V. O. Smirnova

    Published 2020-08-01
    Get full text
    Article

    Save to List
    Saved in:
  19. 19
    Cost-effectiveness analysis of active psoriatic arthritis treatment with ixekizumab in adult patients in Russian Federation health care system

    Cost-effectiveness analysis of active psoriatic arthritis treatment with ixekizumab in adult patients in Russian Federation health care system by E. A. Pyadushkina, E. V. Derkach, M. Yu. Frolov, V. A. Rogov, A. S. Salasyuk

    Published 2021-02-01
    Get full text
    Article

    Save to List
    Saved in:
  20. 20
    PHARMACOECONOMIC EVALUATION OF RIBOCICLIB FOR THE FIRST-LINE TREATMENT OF HR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER

    PHARMACOECONOMIC EVALUATION OF RIBOCICLIB FOR THE FIRST-LINE TREATMENT OF HR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER by N. A. Avksentyev, M. V. Zhuravleva, E. M. Pazukhina, A. V. Snegovoy, M. Yu. Frolov

    Published 2018-08-01
    Get full text
    Article

    Save to List
    Saved in:

Search Tools: